- Home
- TERN vs VALN Comparison
TERN vs VALN Comparison
Compare TERN & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TERN
- VALN
- Stock Information
- Founded
- TERN 2017
- VALN 2012
- Country
- TERN United States
- VALN France
- Employees
- TERN N/A
- VALN N/A
- Industry
- TERN Biotechnology: Pharmaceutical Preparations
- VALN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TERN Health Care
- VALN Health Care
- Exchange
- TERN Nasdaq
- VALN Nasdaq
- Market Cap
- TERN 713.2M
- VALN 777.9M
- IPO Year
- TERN 2021
- VALN 2021
- Fundamental
- Price
- TERN $8.39
- VALN $10.04
- Analyst Decision
- TERN Buy
- VALN Strong Buy
- Analyst Count
- TERN 7
- VALN 4
- Target Price
- TERN $14.99
- VALN $15.75
- AVG Volume (30 Days)
- TERN 1.1M
- VALN 66.2K
- Earning Date
- TERN 11-11-2025
- VALN 11-06-2025
- Dividend Yield
- TERN N/A
- VALN N/A
- EPS Growth
- TERN N/A
- VALN N/A
- EPS
- TERN N/A
- VALN N/A
- Revenue
- TERN N/A
- VALN $230,566,060.00
- Revenue This Year
- TERN N/A
- VALN $15.69
- Revenue Next Year
- TERN N/A
- VALN $22.15
- P/E Ratio
- TERN N/A
- VALN N/A
- Revenue Growth
- TERN N/A
- VALN 25.47
- 52 Week Low
- TERN $1.87
- VALN $3.62
- 52 Week High
- TERN $9.03
- VALN $12.25
- Technical
- Relative Strength Index (RSI)
- TERN 58.46
- VALN 46.82
- Support Level
- TERN $7.91
- VALN $10.08
- Resistance Level
- TERN $9.03
- VALN $10.55
- Average True Range (ATR)
- TERN 0.42
- VALN 0.42
- MACD
- TERN -0.01
- VALN -0.16
- Stochastic Oscillator
- TERN 59.43
- VALN 0.00
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.